ArticleSurgical endoscopy2021
Re-suturing after primary endoscopic sleeve gastroplasty (ESG) for obesity.
Article in Surgical endoscopy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Endoscopic Gastric Mega-plication (MEGA) for the Primary Treatment of Obesity: "A European Multicenter Retrospective Cohort Study, 6-month Outcomes".Obesity surgery · 2026Article
- Redo-Endoscopic Sleeve Gastroplasty for Obesity Treatment: a Multicenter Study on Feasibility, Safety, Efficacy, and Technical Predictors of Outcomes.Obesity surgery · 2026Observational
- The International Federation for Surgery and Other Therapies for Obesity (IFSO) Consensus on Clinical Practice in Endoscopic Sleeve Gastroplasty.Obesity surgery · 2026Article
- Advances and future directions in endoscopic bariatric therapies.World journal of gastrointestinal endoscopy · 2025Review
- Endoscopic Sleeve Gastroplasty: a Proposal for a Minimal Invasive Endoscopic Approach to Adolescent Obesity.Obesity surgery · 2025Review
- Endoscopic Sleeve Gastroplasty: A Retrospective Cohort Study of 90 Patients in Colombia.Obesity surgery · 2025Article
- From Early to Mid-Term Results of Endoscopic Sleeve Gastroplasty: A Retrospective Analysis of a Bariatric Center.Obesity surgery · 2024Article
- Success Predictors of Endoscopic Sleeve Gastroplasty.Obesity surgery · 2024Article
- How to establish an endoscopic bariatric practice.World journal of gastrointestinal endoscopy · 2024Article
- Performance Characteristics of Endoscopic Sleeve Gastroplasty in Patients with Prior Intragastric Balloon: Results of a Propensity Score Matched Study.Obesity surgery · 2023Article
- Advances in endobariatrics: past, present, and future.Gastroenterology report · 2023Review
- Persistence of Sutures and Gastric Reduction After Endoscopic Sleeve Gastroplasty: Radiological and Endoscopic Assessment.Obesity surgery · 2022Article
- Division of a long-term symptomatic tissue bridge for reversal of endoscopic sleeve gastroplasty.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2022Article
- Endoscopic sleeve gastroplasty (ESG) for morbid obesity: how effective is it?Surgical endoscopy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough primary endoscopic sleeve gastroplasty (P-ESG) is effective, some patients may require revision procedures to augment weight loss. We hypothesized that a non-surgical approach using redo ESG (R-ESG) might be a viable option in such patients. We aimed to assess the safety and efficacy of R-ESG following P-ESG to treat obesity.
methodsWe reviewed the outcome of patients who underwent R-ESG at our unit. We classified them as weight loss failure (WF)-< 10% total body weight (TBWL) at 6-months; weight regain (WR)-lost ≥ 10% TBWL and regained 50% of the maximum weight loss at or after 1-year; weight plateau (WP)-lost ≥ 10% TBWL but could not lose further over 3-months. We analyzed the feasibility, safety, and evaluated the efficacy of R-ESG in each group.
resultsOf the 482 patients who underwent P-ESG, 35 (7%) required R- ESG (WF-12, WR-12, WP-11). The mean age, weight, BMI (38.2 kg/m
conclusionThe need for R-ESG after P-ESG is low. R-ESG is safe and induced weight loss in all patients. The maximum benefit was observed in WP.
Indexed as
Identifiers
32583068What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.